Filing Flows › Ionis Pharmaceuticals (IONS) › Guidance history
Ionis Pharmaceuticals (IONS) guidance history: what it guided and what it reported
Ionis Pharmaceuticals gave guidance in 2 earnings releases on file since Apr 29, 2026. Its releases raised guidance twice and lowered it once.
Revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $800M–$825M (Apr 29, 2026) | — | to be reported | — |
The latest quarter
Ionis Pharmaceuticals, Q3 2026: revenue $243M (+55% year over year), operating margin -53.8%, net loss $110M, operating cash flow −$179M. The chart follows the revenue to costs, profit and cash.
Questions
Does Ionis Pharmaceuticals beat its guidance?
Ionis Pharmaceuticals gave guidance in 2 earnings releases on file since Apr 29, 2026. Its releases raised guidance twice and lowered it once.
How often does Ionis Pharmaceuticals raise guidance?
Its earnings releases raised guidance twice and lowered it once since Apr 29, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.